Optimal cut-off value for homeostasis model assessment (HOMA) index of insulin-resistance in a population of patients admitted electively in a portuguese cardiology ward;Limiar do índice homeostasis model assessment (HOMA) para resistência à insulina numa população de doentes admitidos electivamente numa enfermaria portuguesa de cardiologia

Acta Medica Portuguesa

Volumn 27, Issue 4, 2014, Pages 473-479

  Timóteo, Ana Teresa ^a   Miranda, Fernando ^a   Carmo, Miguel Mota ^a   Ferreira, Rui Cruz ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

Author keywords

Glucose tolerance test; Homeostasis; Insulin resistance metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODEL; OBSERVATIONAL STUDY; PORTUGUESE (CITIZEN); RECEIVER OPERATING CHARACTERISTIC; SMOKING; VALIDATION STUDY; ANALYSIS; BIOLOGICAL MODEL; BLOOD; CORONARY CARE UNIT; PORTUGAL;

ADULT; AGED; BLOOD GLUCOSE; CARDIOLOGY SERVICE, HOSPITAL; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; PORTUGAL;

EID: 84906903193     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: 10.20344/amp.5180     Document Type: Article

References (34)

1. The European Health Report 2009. Health and Health Systems. Copenhagen: World Health Organization Regional Office for Europe; 2009.
2. World Health Organization on behalf of the European Observatory of Health Systems and Policies. Health in the European Union. Trends and analysis. Copenhagen: World Health Organization Regional Office for Europe; 2009.
3. Sealy CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab. 2005;90:5698-703.
4. Haymond M.W. Measuring insulin resistance: a task worth doing. But how? Pediatr Diabetes. 2003;4:115-8.
5. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield S.E. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarch: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab. 2001;86:2863-8.
6. Quon M.J. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol Metab. 2001;85:4615-7.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner R.C. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
8. Laakso M. How good marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-65.
9. Wallace TM, Matthews D.R. The assessment of insulin resistance in man. Diabetic Med. 2002;19:527-34.
10. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin. 2001;117:530-3.
11. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader D.J. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004;110:803-9.
12. Vonbank A, Sealy CH, Rein P, Beer S, Breuss J, Boehnel C, et al. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. Clin Chim Acta. 2011;12:1003-7.
13. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski B.I. Two measures of insulin sensivity provided similar information in a U.S. population. J Clin Epidemiol. 2004;57:1214-7.
14. Cigolini M, Seidell J, Targher G, De Slypere JP, Ellsinger BM, Charzewska J, et al. Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: The European Fat Distribution Study. Metabolism. 1995;44:35-40.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckle RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
16. Esteghamati A, Ashraf H, Esteghamati AR, Meysamie A, Khalilzadeh O, Nakhjavani M, et al. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: The implications of metabolic syndrome to detect insulin resistance. Diabet Res Clin Pract. 2009;84:279-87.
17. Otake T, Fukumoto J, Abe M, Takemura S, Mihn PN, Mizoue T, et al. Linking lifestyle factors and insulin resistance, based on fasting plasma insulin and HOMA-IR in middle-aged Japanese men: a cross-sectional study. Scan J Clin Lab Invest. 2014 (in press).
18. Soriguer F, Colomo N, Valdés S, Goday A, Rubio-Martín E, Esteva I, et al. Modifications of the homeostasis model assessment of insulin resistance index with age. Acta Diabetol. 2014 (in press).
19. Sun Y, Li W, Hou X, Wang C, Li C, Zhang X, et al. Triglyceride and ratio of triglycerides to high-density lipoprotein cholesterol are better than liver enzymes to identify insulin resistance in urban middle-aged and older non-obese Chinese without diabetes. Chin Med J. 2014;127:1858-62.
20. Buccini GS, Wolfthal D.L. Valores de corte para índices de insulinorresistencia, insulinosensibilidad e insulinosecreción derivados de la fórmula HOMA y del programa HOMA2. Interpretación de los datos. Rev Arg Endocrinol Metab. 2008;45:3-21.
21. Geloneze B, Vasques ACJ, Stabe CFC, Pareja JC, Rosado LE, Queiroz EC, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome. Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab. 2009;53:281-7.
22. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643-9.
23. Yeni-Komshian H, Caratoni M, Abbasi F, Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-5.
24. Nakai Y, Nakaishi S, Kishimoto H, Seino Y, Nagasaka S, Sakai M, et al. The threshold value for insulin resistance on homeostasis model assessment of insulin sensitivity. Diabet Med. 2002;19:346-7.
25. Ateia S, Rusu E, Cristescu V, Enache G, Cheta DM, Radulian G, et al. Proinsulin and age in general population. J Med Life. 2013;6:424-9.
26. Cuartero BG, Lacalle CG, Lobo CJ, Rey CC, Villar MJA. The HOMA and QUICKI indexes, and insulin and C-peptide levels in healthy children. Cut-off points to identify metabolic syndrome in healthy children. An Pediatrics. 2007;66:481-90.
27. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1995-200.
28. Carr DB, Utzshneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-94.
29. Ascott-Evans B.H. The metabolic syndrome, insulin resistance and cardiovascular disease. SADJ. 2005;60:122-7.
30. Hanley AJ, Karter AJ, Festa A, D'Agostino RJR, Wagenknecht LE, Savage P, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis study. Diabetes. 2002;51:2642-7.
31. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735-42.
32. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64.
33. Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabet. 2013;12:S3.
34. Mojiminiyi OA, Abdella N.A. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med. 2010;48:1629-34.